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Abstract: Epidemiological studies have provided overwhelming evidence for a causal role 
of chronic HBV infection in the development of hepatocellular carcinoma (HCC), but the 
molecular mechanisms underlying virally-induced tumorigenesis remain largely debated. 
In the absence of a dominant oncogene encoded by the HBV genome, indirect roles have 
been proposed, including insertional activation of cellular oncogenes by HBV DNA 
integration, induction of genetic instability by viral integration or by the regulatory protein 
HBx, and long term effects of viral proteins in enhancing immune-mediated liver disease. 
In this chapter, we discuss different models of HBV-mediated liver cell transformation 
based on animal systems of hepadnavirus infection as well as functional studies in 
hepatocyte and hepatoma cell lines. These studies might help identifying the cellular 
effectors connecting HBV infection and liver cell transformation.  
Keywords:  hepatitis B virus; hepatocellular carcinoma; HBx; pathogenesis; 
transformation 
 
1. Introduction  
A number of viruses including the hepatitis B virus (HBV) have been recognized as human 
oncogenic agents   [1,2]. The criteria accepted as establishing causality are based on (i) strong 
epidemiological association; (ii) finding of integrated or episomal viral genomes and gene products in 
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the tumor cells, and (iii) directly oncogenic properties revealed by cell transformation in culture and 
production of tumors in experimental animals. However, the stringency of these criteria differs among 
the various malignancies. The case of HBV and hepatocellular carcinoma (HCC) provides one of the 
most convincing examples of causality based essentially on epidemiologic evidence, using the viral 
surface antigen HBsAg as specific viral marker of persistent infection  [3,4]. Moreover, increased risk 
of developing HCC has been associated with HBsAg-negative HBV infection or occult infection  [5,6]. 
Concerning the second criteria, integrated HBV DNA sequences and episomal HBV genomes have 
been found in a majority of HBV-related tumors  [7,8]. The third criteria however, in vivo direct 
transforming capacities assessed in functional assays, is strikingly weak for HBV compared to other 
human tumor viruses. Thus, for HBV and HCC, as well as for hepatitis C virus (HCV) and HCC, 
etiological relation might be viewed as indirect, being caused by persistent viral replication and 
chronic tissue injury, rather than by inherent oncogenic features of the virus  [2,9]. The role of the 
chronic necro-inflammatory disease induced by immune responses to HBV is largely recognized as a 
major cause of liver cancer. However, other studies have pointed to different procarcinogenic events 
induced more directly by the virus (reviewed in  [10,11]). Notably, the hypothesis of a direct role of 
the virus is supported by the ability of HBV DNA to integrate into the genome of infected cells. 
Genomic changes and insertional activation of cancer-related genes have been shown to result from 
HBV DNA insertion into host chromosomes. Other data argue for a contribution of HBV gene 
products to the tumoral process. Notably, the regulatory protein HBx has been involved in disruption 
of cell cycle regulation, in activation of oncogenic pathways, as well as in induction of DNA damage 
and genetic instability, all features that underlie the liver tumorigenic process (reviewed in  [12]).  
In this article, we summarize some of the findings that support these notions and discuss the 
possible implications for our understanding of HBV-related tumorigenesis.  
2. Animal Models of Hepadnavirus-Related Carcinogenesis 
The human hepatitis B virus is the prototype of the hepadnavirus family, which includes closely 
related viruses infecting a limited number of primates, mammals and birds   [13]. Mammalian 
hepadnavirus models have been extensively used for studying the molecular mechanisms leading to 
liver cancer  [14], as well as for experimenting potential therapeutical approaches in the management 
of HBV infection  [15]. In particular, woodchucks chronically infected with the woodchuck hepatitis 
virus (WHV) have provided a unique model in which viral DNA integration into the host genome 
plays a pivotal role in the tumoral process. 
WHV-infected woodchucks develop chronic hepatitis and HCCs that are in many points similar to 
those associated with HBV infection in humans, although the liver of this rodent species is not 
susceptible to cirrhosis. In experimental inoculations shortly after birth, virtually all woodchucks that 
become chronic WHV carriers develop HCCs with a median tumor-free survival of 24 months and a 
median life expectancy of 30-32 months   [16]. Moreover, HCC occurs in 17% of woodchucks 
serologically recovered from acute infection  [17], and these tumors carry integrated viral sequences. 
These data may be explained by lifelong persistence of “occult” infection after recovery from acute 
hepadnavirus infection   [18]. Related findings have been reported in human HCCs from HBsAg-
negative patients  [19], and it has been reported that occult HBV infection is a risk factor for HCC Viruses 2009, 1                                       
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development  [6]. By contrast, liver tumors are not seen in non-infected woodchucks over their entire 
life span. During preneoplastic stages, WHV replicates at high level in the liver and viral DNA is 
frequently integrated into host chromosomes, leading to clonal expansion of hepatocytes carrying 
integration events  [20,21]. Early preneoplastic lesions consist of altered hepatic foci that overexpress 
N-myc and IGF-II  [22]. At tumoral stage, almost all tumors carry integrated viral sequences that may 
be detected by Southern blotting, reflecting selection by clonal outgrowth of a transformed cell 
targeted by the integration event  [14].  
Search for oncogenes at integration sites in woodchuck HCCs has led us to demonstrate that WHV 
acts mainly as an insertional mutagen of myc family genes. The patterns of WHV DNA insertion in c-
myc in these tumors share common aspects with those of Moloney murine leukemia virus (MLV) in 
murine T-cell lymphomas  [23]. 
Figure 1. Insertional activation of myc genes in WHV-induced woodchuck HCCs.  The c-
myc, N-myc1 and N-myc2 loci are represented as a line with exons as boxes and WHV 
insertion sites are shown with arrows. Under each locus are shown the preferred 
integration sites of retroviruses including murine leukemia virus (MLV), feline leukemia 
virus (FeLV), avian leukemia virus (ALV) and avian reticuloendotheliosis virus (REV). 
The b3n and win loci are located at 10 and 180 kb downstream of N-myc2 on the 
woodchuck X chromosome. Percentages of WHV integration at each locus in a panel of 70 
woodchuck tumors analyzed are shown on the right side. 
 
 
 
The highest frequency of viral integrations was found in the woodchuck N-myc genes, particularly 
in the intronless retroposon N-myc2 and in two nearby loci on the X chromosome called b3n and 
win   [24-28] (Figure 1). Interestingly, integrations targeting the N-myc2 gene have been found 
preferentially in large, advanced stage tumors, highlighting the strong oncogenic activity of N-
myc2  [29]. Besides abnormal, elevated expression levels of the c-myc or N-myc oncogenes, evidence 
for a direct role of Myc activation in woodchuck tumorigenesis came from the finding that virtually all 
transgenic mice carrying WHV insertion sites in c-myc and N-myc2 developed HCC  [30,31]. Myc is Viruses 2009, 1                                       
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required for maintenance and expansion of cancer cells, where it hijacks different programs that drive 
normal cell proliferation. In murine models, Myc proved to be a key contributor to liver 
carcinogenesis, and recent studies have identified c-Myc as a central regulator at the early steps of 
malignant transformation in the human liver  [32]. Thus, integration of WHV DNA confers a selective 
growth advantage on target hepatocytes, leading to the emergence of neoplastic nodules or providing 
an additional step in tumor progression. 
The frequency of tumor incidence in humans and rodents is generally correlated with the fractional 
life span in a similar manner. The average life span of captive healthy woodchucks is about 10 years. 
Hepatocarcinogenesis appears therefore much more rapid and frequent in WHV-infected woodchucks 
than in human HBV carriers, suggesting that WHV might be a more oncogenic virus than HBV. As no 
insertional event into myc genes has been detected so far in human HCCs, the major difference in 
tumorigenicity between the two viruses might be attributed to the unique ability of WHV to provoke 
insertional activation of myc genes  [33].  
3. HBV DNA Integration into Human Chromosomes 
In humans, HBV DNA integration into host chromosomes occurs since early stages in natural acute 
infections  [34,35]. Multiple integrations have been detected in chronic hepatitis tissues  [36,37], and 
integrated HBV sequences have been seen in most (about 80%) HBV-related HCCs  [7,10]. In the 
absence of complete genomes in virtually all HBV inserts, these sequences cannot serve as template 
for viral replication. Integrated forms made of a single subgenomic fragment are believed to represent 
primary products of integration, and are frequent in HCC and hepatitis tissues from children  [35]. 
Single HBV insertions are common in childhood HCCs but are rather uncommon later in life, 
suggesting that multiple integrations accumulate within single cells during long-standing HBV 
infections  [38]. Studies of the organization of cloned HBV inserts in liver tissues and HCCs have 
shown that HBV sequences are often fragmented and rearranged. Moreover, the finding of integration 
and recombination sites dispersed over the viral genome suggests that HBV integration does not occur 
through a unique mechanism, as for integrase-mediated integration of retroviruses. However, highly 
preferred integration sites have been mapped in the HBV genome within the “cohesive ends” region, 
which lies between two 11-bp direct repeats (DR1 and DR2) highly conserved among 
hepadnaviruses  [39]. More specifically, a narrow region encompassing DR1 has been shown to be 
particularly prone to recombination  [40]. It encompasses a short terminal redundancy of the minus-
strand DNA, which confers a triple-stranded structure to the circular viral genome. Accordingly, it has 
been proposed that relaxed circular DNA might be a preferential pre-integration substrate  [41], and 
that Topo I might promote illegitimate recombination of hepadnavirus DNA in vivo  [42]. 
In human HCCs, HBV DNA integration sites have been mapped to multiple regions on virtually all 
chromosomes, suggesting that viral integrations are distributed randomly throughout the host 
genome  [35,43]. These events have multiple consequences either by inducing large-scale chromosome 
changes or by cis-acting effects on the expression or function of nearby cellular genes. Initial studies 
have suggested that HBV insertional mutagenesis is a rare event, and that simple repetitive elements 
such as Alu-type repeats, minisatellite-like, satellite III, or variable number of tandem repeat (VNTR) 
sequences are hotspots for HBV insertion in the human genome. However, evidence for a direct cis-Viruses 2009, 1                                       
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acting promoter insertion mechanism was first provided in two independent HCCs. In one case, the 
HBV insertion targeted the retinoic acid receptor-ß (RARß) gene and resulted in the fusion of 29 
amino-terminal residues of the HBV pre-S1 gene to the DNA-binding and hormone-binding domains 
of RARß   [44,45]. Expression of the tumor-specific chimeric protein has been shown to display 
transforming potential  [46]. In a second HCC, HBV DNA integration occurred in an intron of the 
human cyclin A gene, an essential gene for cell cycle progression, resulting in a strong expression of 
hybrid HBV/cyclin transcripts encoding a stabilized cyclin A  [47,48]. Such modification of cyclin A 
expression has been linked to liver carcinogenesis  [49]. In these two HCC cases, analysis of single 
HBV insertion sites has allowed identifying new genes that play critical roles in the control of cell 
growth and differentiation. Both studies have opened the way to novel approaches of the cellular 
pathways regulating cell division and differentiation. 
More recently, the notion that HBV integrates randomly into human chromosomes has been 
challenged by large-scale analysis of HBV DNA integration sites using the Alu-PCR approach. These 
studies have revealed that targeting of cellular genes by HBV integration is a more frequent event than 
suspected previously  [8,50]. As previously shown for retroviruses  [51,52], HBV DNA integration 
appears to occur frequently in actively transcribed chromosomal regions, within genes or at their 
immediate vicinity. Recently, sequence analysis of 68 viral-host junctions from 60 HCCs provided 
evidence for cellular coding regions within several kbs in 90% of the cases  [8]. Moreover, it was 
shown that HBV integration often targets gene families involved in cell survival, proliferation and 
immortalization, such as hTERT, PDGF receptor, MLL, calcium signaling-related genes and 60s 
ribosomal protein genes. Indeed, recurrent viral insertions nearby the hTERT or MLL gene have been 
reported by different groups   [8,53-55]. Although the functional impact of integrated HBV sequences 
on nearby cellular genes has not been tested in all cases, these data support the view that viral insertion 
might be implicated in one of the multiple steps of liver cell transformation, and that different genes 
targeted by viral integration play important role in the tumoral process. Finally, although integrated 
viral sequences are defective for replication, they might also contribute “in trans” to tumorigenesis 
through the production of truncated and mutated HBx or preS2/S proteins. These proteins may act on 
HCC development by disrupting the control of cellular gene expression or by activating oncogenic 
signaling pathways. 
Besides acting by cis–or trans-activation, HBV insertions have been associated with major genetic 
alterations within the cell genome, including large deletions, duplications and chromosomal 
translocations  [56-60]. The association of HBV integration with large genomic changes might reflect 
the abrogation of control mechanisms that safeguard chromosomal integrity  [61]. In this regard, it is 
interesting to note that HBV-related HCCs have been found to display higher rates of chromosomal 
alterations than HCCs related to other risk factors  [62-64]. Moreover, molecular classification of HCC 
using genome-wide approaches has clearly indicated that HBV-related tumors harbor distinctive 
characteristics such as frequent mutations of the p53 tumor suppressor gene, activation of the mitotic 
cell cycle, deregulated expression of developmental and imprinted genes such as IGF2, and activation 
of the AKT pathway  [64]. In addition, large-scale methodogies have led to conclude that HBV-related 
tumors are often poorly differentiated and present with unfavorable prognosis   [65,66]. At 
preneoplastic stages, distinctive gene expression profiles have been detected in the non-tumoral livers 
of chronic hepatitis B carriers, such as activated expression of genes implicated in pro-apoptotic, Viruses 2009, 1                                       
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inflammatory and DNA repair responses, suggesting specific oncogenic pathways triggered by chronic 
hepatitis B  [67,68]. It seems therefore probable that HBV replication and integration might trigger 
various genomic changes in the infected hepatocytes, playing a role beyond the chronic necro-
inflammatory disease induced by the host immune responses. 
4. Oncogenic Capabilities of the HBx Regulatory Protein 
Among the viral gene products, the HBx protein encoded by the HBV X gene has been termed 
“viral oncoprotein” by many authors, and it has been involved in liver cell transformation because of 
its pleiotropic activities on cell cycle regulation, signaling pathways and DNA repair (reviewed 
in   [69-71]) (Figure 2). However, different studies in cellular and animal models have provided 
divergent data on the transforming abilities of this viral protein. HBx has been reported to transform 
two cell lines immortalized by the simian virus 40 large T antigen (SV40TAg): Rev-2 and a mouse 
fetal hepatocyte cell line   [72,73]. HBx has also been shown to cooperate with Ras in the 
transformation of primary human fibroblasts, either by activating the phosphatidylinositol-3 kinase and 
Akt pathway or by overcoming Ras-induced senescence  [74,75]. A weak tumorigenicity has been 
attributed to HBx in TGF-α immortalized murine hepatocytes, but no cooperation could be evidenced 
with mutated p53  [76]. In contrast, other studies have shown that the apoptotic properties of HBx 
suppress transformation of primary rodent fibroblasts by different oncogenes  [77]. One caveat with 
the observations described above is that most of them were made in cell culture under conditions of 
high levels of X gene expression. Indeed, in the chronically infected liver, HBx expression is kept at 
very low levels, rendering its detection uneasy with most available antibodies  [78]. 
The oncogenic potential of HBx has also been addressed in transgenic mice, with again divergent 
results that probably reflect the use of different murine genetic backgrounds and various promoters 
yielding different expression levels of the viral protein. Development of HCC associated with high-
level expression of HBx in the liver was essentially described for a transgenic mouse line generated in 
the outbred CD-1 background  [79]. In other transgenic lines on different backgrounds, expression of 
HBx by itself did not lead to HCC development, although slight histopathologic alterations could be 
observed in the liver  [80]. 
Transgenic expression of the viral protein cooperates with chemical carcinogens such as diethyl 
nitrosamine (DEN) in accelerating hepatocarcinogenesis  [81]. By crossing HBx mice with WHV/c-
myc oncomice, liver damage was increased and the average tumor latency was shortened by three 
months compared to WHV/c-myc littermates  [82]. This could be explained by the reported ability of 
HBx to protect the c-Myc protein from degradation  [83]. Moreover, HBx knock-in transgenic lines 
generated by homologous recombination into the mouse p21 locus develop HCC  [84]. The CDK 
inhibitor p21
WAF1/Cip1 is a master effector of tumor suppressor pathways that promote cell cycle arrest 
in response to various stimuli, and its genetic ablation might cooperate with HBx in cell 
transformation. Recently, it has been shown that constitutive liver expression of HBx and insulin 
receptor substrate-1 (IRS-1) contribute cooperatively to the development of dysplasia and eventually 
HCC   [85]. The multisite docking protein IRS-1 alone had no direct oncogenic effects, but it 
stimulated hepatocyte proliferation through its central role in the transduction of growth factor signals, 
resulting in the activation of downstream mitogen-activated protein kinase (MAPK) cascade and the Viruses 2009, 1                                       
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Wnt/-catenin pathway in double transgenic mice. Together, these data suggest that HBx alone does 
not behave as a dominant oncogene but rather acts as a co-factor during hepatocarcinogenesis. 
Figure 2. Pleiotropic activities of the regulatory protein HBx. Here we depict a large array 
of HBx functions that may be relevant for cellular transformation, such as stimulation of 
virus replication, cell cycle deregulation, activation of signaling pathways, 
induction/repression of apoptosis and interference with DNA repair. Most of these 
functions are achieved through the transcriptional transactivation activity of HBx or by 
interactions with cellular partners in both cell cytoplasm and nucleus (shown as a grey 
ellipse). 
 
 
The mechanisms implicating HBx in the tumoral process have been investigated in HBx 
transgenic models. It has been shown that hepatic expression of HBx is associated with a significant 
increase in S-phase hepatocytes in young animals but not in adult mice  [86], while our group observed 
increased levels of apoptosis that was independent of p53 in the transgenic livers   [87]. These 
observations are consistent with a model in which HBx stimulates cell cycle progression of quiescent 
G0 cells to the G1/S phase, followed by prolongation of the G1-S transition or cell arrest at the G1/S 
boundary and eventually apoptosis  [88-91]. A similar process might operate during liver regeneration 
after partial hepatectomy, leading to premature cell cycle entry or to impaired regeneration in different 
HBx transgenic lines   [92-94]. Association with severe fat accumulation and impaired glycogen 
storage has been observed in the particular HBx transgenic line that eventually develop HCC  [92], but 
not on other backgrounds. The pathological consequences of cell cycle deregulation by HBx have been 
extensively studied using established hepatocyte and hepatoma cell lines. Viruses 2009, 1                                       
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4. HBx, Replication Stress and Mitotic Defects 
Recent studies have led to a consensus agreement on the fact that HBx interferes with the normal 
control of cell cycle progression. This function may be attributed to the ability of HBx to bind different 
cellular partners and to activate transcription as well as various signaling cascades   [95-99]. The 
impact of HBx on the mitotic phase of the cell cycle seemingly implicates HBx in the induction of 
chromosomal instability (CIN), a hallmark of many tumors that correlates with the presence of extra 
centrosomes. It has been shown that CIN cells with extra centrosomes routinely undergo bipolar cell 
divisions, but display a significantly increased frequency of lagging chromosomes during 
anaphase  [100]. Delayed movement (lagging) during anaphase results in chromosome missegregation, 
as some chromosomes or chromatids fail to be incorporated into one of the daughter nuclei following 
cell division. Accordingly, the observed prolongation of S phase in cells expressing the viral protein 
has been linked to aberrant centrosome duplication, multipolar spindle formation, chromosome 
segregation defects, and appearance of multinucleated cells. 
Interestingly, in some studies these deleterious effects of HBx have been observed in the context 
of viral replication, and they were detectable in dividing, but not in quiescent hepatoma cells  [101]. 
Different mechanisms have been implicated, in particular the interaction of HBx with UV-damaged 
DNA binding protein 1 (DDB1), a protein involved in DNA repair and cell cycle regulation  [101]. 
The ability of HBx to bind DDB1, and the pivotal role of this interaction in viral infectivity and 
replication have been firmly established  [102-104]. DDB1 is a subunit of the E3 ubiquitin ligase Cul4 
complex that serves as an adaptor for selective ubiquitin-dependent degradation of target 
proteins  [105,106]. It is known that anaphase onset and mitosis completion are highly complex and 
coordinated processes governed by dephosphorylation of Cdk substrates and ubiquitination of APC 
substrates. Deregulation of the mechanisms that control protein stability by the viral protein might 
therefore contribute to aberrant cellular growth and tumorigenesis. 
Other studies have shown that HBx effects on centrosome dynamics and mitotic spindle formation 
are associated to the binding of HBx with different cellular partners implicated in centrosome 
formation. It has been reported that HBx interacts with HBXIP, a major regulator of centrosome 
duplication, required for bipolar spindle formation and cytokinesis. This interaction appears to be 
responsible for the formation of defective spindles and subsequent aberrant chromosome 
segregation  [107]. In other report, HBx induces cytoplasmic sequestration of Crm1, a nuclear export 
receptor that binds to Ran GTPase and also localizes at the centrosomes. This interaction seemingly 
results in supernumerary centrosomes, increased frequency of defective mitoses and chromosome 
transmission errors  [108]. Interestingly, recent data have linked DNA re-replication induced by HBx 
to partial polyploidy, known to be associated with cancer pathogenesis   [109]. The mechanisms 
involve simultaneous increase of the replication initiation factors Cdc6 and Cdt1, and downregulation 
of geminin, the inhibitor of replication licensing. Modulation of Cdt1/geminin ratio leads to 
uncontrolled DNA re-replication, DNA damage, and partial polyploidy. The resulting polyploid cells 
are prone to oncogenic transformation that is dependent upon the expression of polo-like kinase 1 
(Plk1), a crucial factor that positively influences mitotic entry  [110]. HBx has also been shown to 
target BubR1, an effector of multiple mitotic kinases that specifies microtubule attachments and 
checkpoint functions  [111]. It is worth noticing that mitotic phosphorylation of BubR1 by Plk1 is Viruses 2009, 1                                       
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known to stimulate BubR1 kinase activity, promoting kinetochore microtubule attachments and 
recruitment of the Mad2 checkpoint protein to kinetochores. Moreover, it has been shown that SV40 
large T antigen (LT) targets Bub1 and this has been correlated with alteration of the spindle checkpoint 
and oncogenic transformation.  
Although the precise HBx activities that interfere with the mitotic cell cycle remain to be 
determined, these data provide insight into possible mechanisms leading to deregulation of the cellular 
mitotic machinery by a viral protein. They also provide a strong link between HBx expression and 
chromosomal instability in HBV-related carcinogenesis. 
Conclusions  
Cancer arises from stepwise accumulation of genetic changes that confer unlimited, self-sufficient 
growth and resistance to normal homeostatic mechanisms. The long latency of HCC development after 
the primary HBV infection may be interpreted as a sign of an indirect action of the virus. It is 
generally admitted that host immune responses against infected hepatocytes triggers continuous 
necrosis and cell regeneration, leading to chronic inflammatory disease that in turn favors the 
accumulation of genetic alterations. In this view, long-term toxic effect of viral gene products, notably 
the HBx protein, as well as exogenous carcinogens such as aflatoxins and alcohol, potentiate the action 
of chronic liver inflammation. However, tumor onset might also depend on the occurrence of a 
decisive HBV integration event that would promote genetic instability or lead to cis- or trans-
activation of cancer-related genes. The large variety of pathological properties attributed to the viral 
protein HBx indicates that multiple cooperative mechanisms may operate in the development of liver 
cancer. Future studies identifying more precisely the cellular effectors that mediate the tumorigenic 
effects of HBV are poised to advance the field of liver cancer biology and to develop adapted 
therapeutic strategies. 
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